Table 2.
Base Case Results
Usual Care | Tafamidis | |
---|---|---|
Healthcare Outcomes | ||
Survival, life years (undiscounted) | 3.46 (2.88 – 4.25) | 5.43 (4.17 – 6.76) |
Survival, life years (discounted) | 3.23 (2.73 – 3.84) | 4.83 (3.82 – 5.79) |
Incremental life years (discounted) | Comparator | 1.60 (0.48 – 2.47) |
Quality-adjusted survival, QALYs (discounted) | 2.19 (1.94 – 2.56) | 3.48 (2.85 – 4.15) |
Incremental QALYs (discounted) | Comparator | 1.29 (0.47 – 1.75) |
Cardiovascular Hospitalizations, number | 2.36 (1.87 – 3.02) | 2.53 (1.78 – 3.43) |
Direct Healthcare Costs | ||
Lifetime Healthcare Costs, 2019 USD (discounted) | 126,000 (105,000 – 157,000) | 1,262,000 (996,000 – 1,515,000) |
Spending on Tafamidis | - | 1,086,000 (861,000 – 1,303,000) |
Spending on CV Hospitalizations | 34,000 (26,000 – 46,000) | 34,000 (23,000 – 47,000) |
Background Healthcare Costs | 92,000 (77,000 – 113,000) | 142,000 (110,000 – 174,000) |
Incremental healthcare costs, 2019 USD (discounted) | Comparator | $1,135,000 (872,000–1,377,000) |
ICER, USD per life-year gained | Comparator | $709,000 (547,000 – 1,943,000) |
ICER, USD per QALY gained | Comparator | $880,000 (697,000–1,564,000) |
Abbreviations: ICER = incremental cost-effectiveness ratio; USD = United States Dollar; QALY = quality-adjusted life year.